AC Immune SA (IMR.SG)
| Previous close | 2.1080 |
| Open | 2.1730 |
| Bid | 2.1630 x 0 |
| Ask | 2.2250 x 0 |
| Day's range | 2.1730 - 2.1730 |
| 52-week range | 1.5745 - 4.2780 |
| Volume | |
| Avg. volume | 2,153 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
- GlobeNewswire
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first, low dose cohortACI-24.060 was generally well tolerated with no safety concerns observedWith these findings, dosing in the second, higher dose Alzheimer’s cohort has begunScreening of cohort of study participants with Down syndrome also cleared to beginFurther safety and immunogenic
- GlobeNewswire
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3 trialPI-2620 potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregated TauTau accumulation, a key Alzheimer's disease pathology, correlates with cognitive impairment Lausanne, Switzerland, January 18, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharm
